The investigational Evident test requires 3 tumor markers on the same extracellular vesicle to flag early-stage ovarian cancer.
|Articles|June 9, 2016
Talc lawsuits: Will they change recommendations? (VIDEO)
Author(s)Bobby Lazzara, MD
For Contemporary OB/GYN, Dr Bobby Lazzara discusses the recent lawsuits that claim talc powder usage led to ovarian cancer and how it may affect your recommendations.
Advertisement
For Contemporary OB/GYN, Dr Bobby Lazzara discusses the recent lawsuits that claim talc powder usage led to ovarian cancer and how it may affect your recommendations.
Advertisement
Related to this article
Cultural upbringing gives context to sexual dysfunction but does not make the diagnosis, according to Sameena Rahman, MD, FACOG.
In September, the FDA accepted an extended duration sNDA for the IUD with a decision expected in Q2 2027.
Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.
Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
Matthew Nudy, MD, on estrogen and the cardiovascular system
3
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
4
Susan Reed, MD, on the future of menopause research and funding
5